Rethinking the 10‐pack‐year rule for favorable human papillomavirus–associated oropharynx carcinoma: A multi‐institution analysis

Cancer ◽  
2020 ◽  
Vol 126 (12) ◽  
pp. 2784-2790
Author(s):  
James R. Broughman ◽  
David D. Xiong ◽  
Benjamin J. Moeller ◽  
Kevin J. Contrera ◽  
Brandon L. Prendes ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharynx Carcinoma

Human papillomavirus oropharynx carcinoma: Aggressive de‐escalation of adjuvant therapy

Head & Neck ◽  
2020 ◽  
Vol 43 (1) ◽  
pp. 229-237
Author(s):  
Eric J. Moore ◽  
Kathryn M. Van Abel ◽  
David M. Routman ◽  
Christine M. Lohse ◽  
Katharine A. R. Price ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Adjuvant Therapy ◽  
Oropharynx Carcinoma

P.229 Human papillomavirus association with the oral cavity and oropharynx carcinoma

2006 ◽  
Vol 34 ◽  
pp. 191
Author(s):  
P. Jeremic ◽  
M. Dimitrijevic ◽  
T. Jovanovic ◽  
A. Knezevic
Keyword(s):  
Human Papillomavirus ◽  
Oral Cavity ◽  
Oropharynx Carcinoma

Oncologic outcomes of human papillomavirus–associated oropharynx carcinoma treated with surgery alone: A 12‐institution study of 344 patients

Cancer ◽  
2021 ◽  
Author(s):  
William R. Ryan ◽  
Mary J. Xu ◽  
Edgar Ochoa ◽  
Karolina A. Plonowska‐Hirschfeld ◽  
Aaron L. Zebolsky ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oncologic Outcomes ◽  
Oropharynx Carcinoma

Comparison of the 7 th and 8 th Editions of the AJCC/UICC Staging for Human Papillomavirus–Related Oropharynx Carcinoma

2018 ◽  
Vol 100 (5) ◽  
pp. 1351
Author(s):  
K. Casper ◽  
P.G. Hawkins ◽  
M. Mierzwa ◽  
E. Bellile ◽  
K. Malloy ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharynx Carcinoma

Predicting Adverse Histopathology and Need for Postsurgical Adjuvant Therapy for Human Papilloma Virus–Associated Oropharynx Carcinoma

2021 ◽  
pp. 019459982098291
Author(s):  
Edgar Ochoa ◽  
Gaelen Stanford-Moore ◽  
Carole Fakhry ◽  
William R. Ryan
Keyword(s):  
Human Papillomavirus ◽  
Adjuvant Therapy ◽  
Predictive Value ◽  
Adjuvant Radiation ◽  
Nodal Staging ◽  
Seventh Edition ◽  
Extranodal Extension ◽  
American Joint Committee ◽  
Oropharynx Carcinoma ◽  
Definitive Surgery

Objective For human papillomavirus–associated oropharynx carcinoma treated with definitive surgery, we aimed to find predictors of adverse histopathology indicating the possible need for adjuvant therapy. Study Design Retrospective review. Setting National Cancer Database. Methods We analyzed 2347 eligible patients from 2010 to 2015. We evaluated (1) the ability of clinical nodal staging and extranodal extension designation per the AJCC, seventh edition (American Joint Committee on Cancer), to predict histopathology and (2) the likelihoods for adverse postsurgery histopathology by common clinical stages. Results Clinical nodal staging predicted pathologic nodal staging 65% of the time, with 24% (569/2347) being upstaged and 11% (251/2347) being downstaged. In patients with cN+ disease, clinical extranodal extension distinction had the following accuracy for pathologic extranodal extension: positive predictive value, 81% (88/109); negative predictive value, 73.1% (505/691); sensitivity, 32.1% (88/274); and specificity, 96.0% (505/526). Patients with cT1-2, N0-N2c, without clinical extranodal extension had the following proportions of pN2+ without pathologic extranodal extension (indicating consideration for adjuvant radiation): cN0, 11%; cN1, 31%; cN2a, 67% (8% downstaged); cN2b, 66% (6% downstaged); and cN2c, 35% (17% downstaged). From this group, patients had the following proportions of pathologic extranodal extension (indicating consideration for adjuvant chemoradiation): cN0, 6%; cN1, 20%; cN2a, 27%; cN2b, 28%; and cN2c, 48%. Conclusion For human papillomavirus–associated oropharynx carcinoma, nodal clinical staging per the American Joint Committee on Cancer, seventh edition, predicts pathologic stage about two-thirds of the time, leading to up- and downstaging. Clinical extranodal extension assessment has low sensitivity and moderate predictive capability. With careful selection, definitive surgery can allow patients to often avoid adjuvant chemotherapy and sometimes avoid adjuvant radiation.

A combined ultrastructural and gene molecular research for the relationship between human uterine cervical carcinoma and human papillomavirus

1990 ◽  
Vol 48 (3) ◽  
pp. 204-205
Author(s):  
Kun Lee ◽  
Jingyi Si ◽  
Ricai Han ◽  
Wei Zhang ◽  
Bingbing Tan ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Intraepithelial Neoplasia ◽  
Hpv Infection ◽  
Dot Blot ◽  
Homologous Sequences ◽  
Normal Cervical Epithelium ◽  
The Relationship ◽  
Chronic Cervicitis

There are more supports for the view that human papillomavirus (HPV) infection might be an etiological factor in the development of cervical cancer when the association of persistent condylomata is considered. Biopsies from 318 cases with squamous cell carcinoma of uterine cervix, 48 with cervical and vulvar condylomata, 14 with cervical intraepithelial neoplasia (CIN), 34 with chronic cervicitis and 24 normal cervical epithelium were collected from 5 geographic regions of China with different cervical cancer mortalities. All specimens were prepared for Dot blot, Southern blot and in situ DNA-DNA hybridizations by using HPV-11, 16, 18 DNA labelled with 32P and 3H as probes to detect viral homologous sequences in samples. Among them, 32 cases with cervical cancer, 27 with condyloma and 10 normal cervical epitheliums were randomly chosen for comparative EM observation. The results showed that: 1), 192 out of 318 (60.4%) cases of cervical cancer were positive for HPV-16 DNA probe (Table I)

Epidemiology of Human Papillomavirus Infection

2000 ◽  
Vol 34 (6) ◽  
pp. 194-200 ◽  
Author(s):  
Joakim Dillner ◽  
Chris J. L. M. Meijer ◽  
Geo von Krogh ◽  
Simon Horenblas
Keyword(s):  
Human Papillomavirus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection
Sign in / Sign up

Export Citation Format

Share Document